27 search results for: disease control
Giselle Mosnaim, MD, MS, FAAAAI, FACAAI
Giselle Mosnaim is a board-certified allergist and immunologist at Endeavor Health and Clinical Assistant Professor at the University of Chicago Pritzker School of Medicine. An internationally recognized expert in asthma and allergic diseases, her clinical and research interests focus on severe and uncontrolled asthma, digital health, and improving patient outcomes through innovative, evidence-based care.
Connecting Type 2 Inflammation to CRSwNP
Prof. Claus Bachert describes how type 2 inflammation drives CRSwNP.
Insights From Dr Lawrence Eichenfield on the 2026 IEC Consensus Definition for Low Disease Activity and Remission for Atopic Dermatitis
Hear Dr. Lawrence Eichenfield share the recent consensus definitions from the International Eczema Council.
Essential Tools for Effective Care of Patients With Chronic Spontaneous Urticaria
Tune in as Dr. Jason Hawkes describes how to assess disease activity in chronic spontaneous urticaria.
ADVENT On Air | The Road Ahead: Achieving Remission for Patients With Asthma
Join Professors Klaus Rabe and Ian Pavord as they discuss the importance of on-treatment clinical remission as a goal in asthma management.
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis
Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.
Partnering With Patients: Scores That Matter in CRSwNP
Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life
ERS-ISIAN 2025 | Treatable Traits in CRSwNP
Join Prof. Sietze Reitsma for an insightful presentation that will delve into identifying and leveraging key characteristics to optimize patient management and treatment outcomes.
Loss of Smell is a Key Symptom of CRSwNP
Learn how loss of smell in CRSwNP is a key symptom for both patients and providers.
Understanding Barriers to Advanced Systemic Therapy in AD
Dr. Jean-David Bouaziz highlights a study describing barriers to initiating advanced systemic therapy for AD at EADV 2025
Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson outlines why early, targeted control of type 2 inflammation may modify the course of atopic dermatitis by addressing upstream drivers of barrier dysfunction, dysbiosis, and itch.
